CY1107937T1 - Προφαρμακα σε συνδετες υποδοχεα nmda - Google Patents

Προφαρμακα σε συνδετες υποδοχεα nmda

Info

Publication number
CY1107937T1
CY1107937T1 CY20081100485T CY081100485T CY1107937T1 CY 1107937 T1 CY1107937 T1 CY 1107937T1 CY 20081100485 T CY20081100485 T CY 20081100485T CY 081100485 T CY081100485 T CY 081100485T CY 1107937 T1 CY1107937 T1 CY 1107937T1
Authority
CY
Cyprus
Prior art keywords
nmda
connectors
products
compounds
lower alkyl
Prior art date
Application number
CY20081100485T
Other languages
Greek (el)
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Holger Fisher
Neidhart Marie-Paule Heitz
Joerg Huwyler
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1107937T1 publication Critical patent/CY1107937T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20081100485T 2000-08-21 2008-05-08 Προφαρμακα σε συνδετες υποδοχεα nmda CY1107937T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
EP01965201A EP1313703B1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Publications (1)

Publication Number Publication Date
CY1107937T1 true CY1107937T1 (el) 2013-09-04

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100485T CY1107937T1 (el) 2000-08-21 2008-05-08 Προφαρμακα σε συνδετες υποδοχεα nmda

Country Status (35)

Country Link
US (1) US6407235B1 (cg-RX-API-DMAC7.html)
EP (1) EP1313703B1 (cg-RX-API-DMAC7.html)
JP (1) JP4162991B2 (cg-RX-API-DMAC7.html)
KR (1) KR100589991B1 (cg-RX-API-DMAC7.html)
CN (1) CN1227230C (cg-RX-API-DMAC7.html)
AR (1) AR030373A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386022T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001285894B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113348A (cg-RX-API-DMAC7.html)
CA (1) CA2419279C (cg-RX-API-DMAC7.html)
CY (1) CY1107937T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303319B6 (cg-RX-API-DMAC7.html)
DE (1) DE60132782T2 (cg-RX-API-DMAC7.html)
DK (1) DK1313703T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP034489A (cg-RX-API-DMAC7.html)
EG (1) EG24293A (cg-RX-API-DMAC7.html)
ES (1) ES2299508T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20030125B1 (cg-RX-API-DMAC7.html)
HU (1) HU229802B1 (cg-RX-API-DMAC7.html)
IL (1) IL154254A0 (cg-RX-API-DMAC7.html)
JO (1) JO2289B1 (cg-RX-API-DMAC7.html)
MA (1) MA26947A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001311A (cg-RX-API-DMAC7.html)
MY (1) MY136065A (cg-RX-API-DMAC7.html)
NO (1) NO324941B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ523990A (cg-RX-API-DMAC7.html)
PA (1) PA8525601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20020291A1 (cg-RX-API-DMAC7.html)
PL (1) PL204215B1 (cg-RX-API-DMAC7.html)
PT (1) PT1313703E (cg-RX-API-DMAC7.html)
RS (1) RS51467B (cg-RX-API-DMAC7.html)
RU (1) RU2272027C2 (cg-RX-API-DMAC7.html)
SI (1) SI1313703T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002016321A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300894B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2245876C2 (ru) * 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CN101374801B (zh) * 2005-12-19 2014-07-02 梅特希尔基因公司 用于增强抗真菌剂活性的组蛋白脱乙酰酶抑制剂
JP2010513326A (ja) 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9408506A (pt) * 1994-01-31 1997-08-05 Pfizer Compostos neuroprotetores
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
CA2419279C (en) 2008-10-14
HUP0301548A3 (en) 2010-03-29
EP1313703A1 (en) 2003-05-28
JO2289B1 (en) 2005-09-12
NO324941B1 (no) 2008-01-07
KR20030022417A (ko) 2003-03-15
CA2419279A1 (en) 2002-02-28
SI1313703T1 (sl) 2008-06-30
RU2272027C2 (ru) 2006-03-20
DE60132782T2 (de) 2009-02-05
PE20020291A1 (es) 2002-04-17
KR100589991B1 (ko) 2006-06-15
EP1313703B1 (en) 2008-02-13
CZ303319B6 (cs) 2012-08-01
YU13003A (sh) 2006-05-25
JP4162991B2 (ja) 2008-10-08
NZ523990A (en) 2004-09-24
PL361387A1 (en) 2004-10-04
CN1447793A (zh) 2003-10-08
AU2001285894B2 (en) 2006-06-15
HRP20030125A2 (en) 2005-02-28
BR0113348A (pt) 2003-07-08
US6407235B1 (en) 2002-06-18
ZA200300894B (en) 2004-04-30
JP2004506715A (ja) 2004-03-04
CN1227230C (zh) 2005-11-16
PT1313703E (pt) 2008-03-25
AR030373A1 (es) 2003-08-20
MA26947A1 (fr) 2004-12-20
AU8589401A (en) 2002-03-04
HK1059083A1 (en) 2004-06-18
DK1313703T3 (da) 2008-05-19
PL204215B1 (pl) 2009-12-31
EG24293A (en) 2009-01-08
RS51467B (sr) 2011-04-30
NO20030781D0 (no) 2003-02-19
CZ2003492A3 (cs) 2004-01-14
ES2299508T3 (es) 2008-06-01
MXPA03001311A (es) 2003-06-30
WO2002016321A1 (en) 2002-02-28
PA8525601A1 (es) 2002-04-25
HUP0301548A2 (hu) 2003-08-28
NO20030781L (no) 2003-02-19
DE60132782D1 (de) 2008-03-27
US20020040037A1 (en) 2002-04-04
ATE386022T1 (de) 2008-03-15
MY136065A (en) 2008-08-29
HU229802B1 (hu) 2014-07-28
IL154254A0 (en) 2003-09-17
HRP20030125B1 (en) 2011-07-31
ECSP034489A (es) 2003-03-31

Similar Documents

Publication Publication Date Title
DK1485359T3 (da) Natriumkanalblokkere
BR0314227A (pt) Derivados de amido de hidroxialquila
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
CY1109220T1 (el) Παραγωγα ν-ακυλαμινοβενζολιου ως εκλεκτικοι αναστολεις της οξειδασης μονοαμινης β
DK633088A (da) Kollagenaseinhibitorer
CO4980887A1 (es) Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
NO954609D0 (no) Niopecotiske syrederivater som antitrombiske forbindelser
FI101301B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahydroatsepiinijohdannaisten valmistamiseksi
ATE312150T1 (de) Electrochrome lösung, enthaltend eine hydrazonverbindung und mit dieser hergestellte vorrichtung
IT1275997B1 (it) Enammine come accelleranti di vulcanizzazione per gomme naturali o sintetiche
DK1663122T3 (da) Mundskyllesammensætninger indeholdende N-acyl-argininalkylestersalte
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
CY1105786T1 (el) Εκδοχα φλαβονων η διαδικασια παρασκευης τους, η εφαρμογη τους ως φαρμακα
ITMI913400A1 (it) Acidi triazinilfosfonici e loro impiego in composizioni polimeriche autoestinguenti.
YU13003A (sh) Prolekovi za ligande nmda receptora
DE69405439D1 (de) Verfahren zur Herstellung von Aminotriazin-Derivaten
ATE6500T1 (de) 2-alpha-methyl-dopaminimino-6,7-dihydroxy-1,2,3 4-tetrahydronaphthalin, seine salze, und verfahren zu dessen herstellung.
ATE222583T1 (de) Derivate substituierter amidinonaphthylester
ES8504680A1 (es) Un procedimiento para la preparacion de derivados de benzamida
GR930100500A (el) Παράγωγα φαινυλοξικού οξέως, διεργασία για την παρασκευή τους και αντίστοιχη χρήση.
IL150100A0 (en) Pharmaceutical compositions containing fused cyclic compounds
CY1105422T1 (el) Νεα πιπepιδινυλο-αλκυλαμινο-πυριδαζινονικα παραγωγα, μια διαδικασια για την παρασκευη τους και φαρμακευτικες συνθεσεις οι οποιες πepιεχουν τις εν λογω ενωσεις
FR2794122B1 (fr) Nouveaux antioxydants, procedes de preparation et utilisations
ATE231161T1 (de) 6-deoxy-erythromycin-derivate, ihrer herstellung, und ihrer verwendung als arzneimitteln